Abstract
Chromatin interactions between cis-regulatory elements (CREs) and specific gene promoters offer insights into the mechanisms of gene activation and repression. This knowledge is crucial for evaluating the effects of non-coding variants and chromatin alterations in cell differentiation or disease. Experimental techniques Hi-C and single-cell Hi-C provide information on CRE-promoter interactions, but the high costs and labor requirements limit their widespread use. We introduce UniversalEPI, an attention-based neural network designed to predict CRE-promoter interactions up to 2 Mb apart across unseen cell types without model retraining and using only DNA sequence and chromatin accessibility data as input. In UniversalEPI, chromatin accessibility profiles with masked non-accessible regions and DNA sequence data get passed through several convolution layers to identify binding motifs of three key transcription factors ubiquitously involved in promoter activation and CRE-promoter looping; a transformer block then takes the information from the convolutional levels passed through stochastic gating to predict chromatin interactions. While being a relatively lightweight model because of its architecture, UniversalEPI outperforms the state-of-the-art methods in inferring CRE-promoter interactions in unseen cell types across human cancerous and non-cancerous cell lines (Spearman’s Rho > 0.92). The model can also incorporate pseudo-bulk chromatin accessibility data from single-cell ATAC-seq experiments to pinpoint cell subtypespecific interactions. We illustrate the ability of UniversalEPI to track the dynamics of CRE-promoter interactions during macrophage reprogramming and the transition between cancer transcriptional states in esophageal adenocarcinoma. UniversalEPI thus advances in-silico 3D chromatin modeling, supporting studies of chromatin dynamics in cell differentiation and impacts of non-coding variants.
Competing Interest Statement
F.J.T. consults for Immunai Inc., Singularity Bio B.V., CytoReason Ltd, and Omniscope Ltd, and has ownership interest in Dermagnostix GmbH and Cellarity. I.L.I. currently works at Bioptimus.